Shilpa Medicare has completed US Food and Drug Administration (USFDA) audit at its API site, Raichur between July 22, 2019 and July 26, 2019. The company has received Form 483 with 5 observations, with no repeat observations and any data integrity observations. The observations are mostly procedural in nature.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
